-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81

Benzinga·09/23/2026 13:17:37
Listen to the news
Leerink Partners analyst David Risinger maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and lowers the price target from $90 to $81.